DoD Peer Reviewed Orthopaedic, Applied Research Award | W81XWH 21 PRORP ARA

Opportunity Information: Apply for W81XWH 21 PRORP ARA

The DoD Peer Reviewed Orthopaedic Research Program (PRORP) Applied Research Award (ARA) for FY21 is a funding opportunity from the Department of Defense (Department of the Army, USAMRAA) that supports applied, near-term research aimed at improving care for musculoskeletal injuries that occur during combat, combat-related activities, and non-battle situations that still affect unit readiness. The central goal is practical: advance treatment and restore function so injured service members can receive effective care closer to the point of injury and/or return to duty or work faster. While the military need is the priority, the program also expects that successful outcomes will translate to benefits for civilians dealing with similar orthopaedic and musculoskeletal problems.

A key requirement is that every application must directly align with one of the FY21 PRORP ARA Focus Areas (listed in the full announcement under Section II.A.1). This mechanism is explicitly not meant for open-ended discovery science. Instead, it is designed for projects that take promising ideas, early evidence, or prototypes and push them toward something that can realistically move into clinical use. In other words, the program is looking for work that bridges the gap between concepts and real-world medical solutions, with a clear path toward clinical translation.

The award emphasizes applied research, meaning studies should be aimed at refining and testing potential solutions and determining whether they are technically feasible and ready to progress. Examples of the kinds of outputs the DoD is looking for include knowledge products that can shape practice, pharmacologic agents, biologics, rehabilitation and behavioral interventions, diagnostic methods, therapeutic techniques, clinical guidance, and emerging technologies or tools that could plausibly be adopted in a care setting. Projects may be small or large in scope, but they are expected to produce results that meaningfully advance a candidate intervention, tool, or approach toward the clinic rather than simply generating basic scientific insights.

Competitiveness depends heavily on evidence and scientific rigor. Applicants are required to include preliminary and/or published data that directly support the proposed direction. The proposal must show logical reasoning, a strong scientific rationale, and a clearly stated, testable hypothesis that is grounded in a careful analysis of existing literature. The emphasis here is on demonstrating that the project is ready for an applied research mechanism: the idea should not be speculative, and the plan should make sense as the next step toward a deliverable that could later be tested clinically.

Within that applied framework, the solicitation allows several types of work. Projects can focus on refining concepts into workable solutions or research tools, specifically to evaluate feasibility of new approaches and technologies. They can also include evaluation, maturation, and down-selection of product candidates such as drugs, biologic constructs, or devices and systems, using in vitro and/or in vivo testing to decide which candidates are most promising. In addition, the program supports preparation activities that set the stage for a future clinical trial or a regulatory submission, which signals that the DoD wants investigators to think beyond the immediate experiments and plan for what it will take to transition the work into real-world use.

At the same time, the award has a firm boundary: funds cannot be used for fundamental basic research. The announcement defines basic research as work aimed at understanding underlying phenomena without a specific application or product in mind. Put simply, proposals need to be oriented toward a practical endpoint, not just new knowledge for its own sake.

Funding is provided through assistance agreements, which can be structured as either a grant or a cooperative agreement. The deciding factor is how involved the DoD expects to be during the project. If substantial agency involvement is not anticipated, the award is typically a grant. If the DoD anticipates substantial involvement, such as collaboration or participation in the research, then a cooperative agreement is used, and the specific nature of that involvement is spelled out in the award. The final award type and start date are set during negotiations.

Budget-wise, the anticipated total cost for the entire period of performance for a single FY21 PRORP ARA project is capped at $725,000 (with additional details referenced in the Funding Restrictions section of the full announcement). Programmatically, the CDMRP planned to allocate about $2.90 million total to support roughly four awards, meaning the competition is selective and funding depends on federal availability, the number of submissions, and how proposals score in both scientific peer review and programmatic review. The original application closing date for this FY21 opportunity was September 10, 2021, and awards were expected to be made no later than September 30, 2022. The funds were anticipated to come from FY21 appropriations, with availability through September 30, 2027, reflecting the limited window in which the government can obligate and use those fiscal-year funds.

Eligibility is described as unrestricted, meaning it is broadly open to many entity types (subject to any additional clarifications in the full eligibility language). The opportunity is listed under Assistance Listing (CFDA) 12.420 and falls under science and technology and other research and development activities, reinforcing that this is a research-driven program with a strong emphasis on translational, implementation-minded outcomes rather than exploratory basic science.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Applied Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 01, 2021.
• Applicants must submit their applications by Sep 10, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PRORP ARA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: